PakVac is the first COVID-19 vaccine to be processed in Pakistan. This vaccine was developed by China’s government-owned pharmaceutical company Cansino. It was obtained in a concentrated form by the National Institute of Health in Islamabad to be packaged.
This vaccine is also the first Chinese vaccine to undergo clinical trials in Pakistan. After being tested in Pakistan and several other nations, its interim efficacy was found to be 65.7 per cent, capable of preventing symptomatic coronavirus cases. Its success rate of preventing severe COVID-19 infections was found to be 90.98 per cent.